Proof positive that Tony Fauci and the Democrat Leadership were aware as of March 16, 2020 Hydroxychloroquine was curing COVID-19 Patients !

—————————–

“SOMETHING IS VERY ROTTEN IN DENMARK “

Yet Four Days Later He Publicly Rebuked President Trump at W.H. Presser For Suggesting It as a Valid COVID Treatment along with the Democrat Party and their controlled Social Media (1) .

———————————–

“Dr. Fauci and the bipartisan establishment deliberately obstructed President Trump’s advocacy for hydroxychloroquine (HCQ), an affordable treatment option during the COVID-19 pandemic. They favored the much more expensive drug, Remdesivir, priced at $1,000 per dose compared to HCQ’s modest $0.70. ….”  

https://x.com/NotAlexSheppard/status/1797736749910597677?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1797740844750868756%7Ctwgr%5Ed019d7e877efb64a0ae10cd0b8767074e574cccb%7Ctwcon%5Es2_&ref_url=https%3A%2F%2Fwww.thegatewaypundit.com%2F2024%2F06%2Fkiller-fauci-march-16-2020-dr-fauci-received%2F

=================                                                                                                                                             Dr. Tony Fuaci’, FDA AND CDC issued ‘A Mandated COVID-19 Drug Treatment and Protocol Decree ‘ issued to every Medical Doctor and Facility  that REMDESIVIR was the only APPROVED TO USE.  Dr. Bryan Ardis exposed the fact that REMBESIVIR was the only drug relected by the EBOLA SAFETY BOARD BECAUSE IT HAD THE HIGHEST RATE OF HEART AND KIDNEY FAILURES and once the Kidneys fail fluids begin to build in the lungs and then when the patient is placed on a  ventilator they are being drowned to their death in their own fluids. Dr. Ardis also reported that Dr. Tony Fauci hold PATENT INTEREST AND THUS HAS BEEN BENEFITING FROM A MAJOR VERT LUCRATIVE REVENUE STREAM OF ROYALTY FOR THE USE OF THE DRUG REMDESIVIR.

=================

At the same time National Institute of Health had been conducting their own research  posted the following report on their Web Library:

“In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Xueting Yao ¹ , Fei Ye ² , Miao Zhang ¹ , Cheng Cui ¹ , Baoying Huang ² , Peihua Niu ² , Xu Liu ¹ , Li Zhao ² , Erdan Dong ³ , Chunli Song ⁴ , Siyan Zhan ⁵ , Roujian Lu ² , Haiyan Li ^{1 3} , Wenjie Tan ² , Dongyang Liu ¹

Affiliations

• PMID: 32150618
• PMCID: PMC7108130
• DOI: 10.1093/cid/ciaa237

Abstract

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.

Methods: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2-infected Vero cells. Physiologically based pharmacokinetic (PBPK) models were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug’s safety profile.

Results: Hydroxychloroquine (EC50 = 0.72 μM) was found to be more potent than chloroquine (EC50 = 5.47 μM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.

Conclusions: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.”

https://pubmed.ncbi.nlm.nih.gov/32150618/

========================

REFERENCE AND SOURCE

(1)